A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for the pharmaceutical company that plaintiffs lacked subject-matter jurisdiction.

UMB Bank NA filed suit against Bristol-Myers in 2021, alleging that the company intentionally slow-rolled the approval process for a cancer drug in order to dodge paying the more than $6 billion owed to former Celgene shareholders under a contingent value rights agreement.